Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-02: Form 8-K; Period of report 2017-11-02; Description 3.02 Unregistered Sales of Equity Securities; Details 3.02.
- 2017-11-01: Form 8-K; Period of report 2017-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-08-02: Form 8-K; Period of report 2017-08-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-07-07: Form 8-K; Period of report 2017-07-06; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-02 | 8-K | 2017-11-02 | 3.02 Unregistered Sales of Equity Securities | 3.02 On October 26, 2017, the previously disclosed settlement of the consolidated purported class action litigation, captioned Medina v. | d483102d8k.htm |
| 2017-11-01 | 8-K | 2017-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2017, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2017. | a51709463.htm |
| 2017-08-02 | 8-K | 2017-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2017, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2017. | a51619242.htm |
| 2017-07-07 | 8-K | 2017-07-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) Compensatory Arrangements of Certain Officers. | d423104d8k.htm |
| 2017-06-26 | 8-K | 2017-06-20 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On June 20, 2017, Clovis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of 3,409,091 shares of common stock, par value $0.001 per share, of the Company. 8.01 On June 19, 2017, the Company issued a press release announcing the commencement of the offering. | d408101d8k.htm |
| 2017-06-19 | 8-K | 2017-06-18 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 The information set forth in Item 8.01 below is incorporated by reference into this Item 3.02. 8.01 On June 18, 2017, the Company entered into a stipulation and agreement of settlement that is intended to settle the previously disclosed consolidated purported class action litigation captioned Medina v. | d389567d8k.htm |
| 2017-06-08 | 8-K | 2017-06-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Shareholders (the “Annual Meeting”) of Clovis Oncology, Inc. (the “Company”) was held on June 8, 2017. | d329793d8k.htm |
| 2017-05-03 | 8-K | 2017-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 03, 2017, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2016. | a51552708.htm |
| 2017-02-22 | 8-K | 2017-02-22 | 2.02 Results of Operations and Financial Condition | 2.02 On February 22, 2017, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2016. | a51514483.htm |
| 2017-02-01 | 8-K | 2017-01-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a51502871.htm |
| 2017-01-09 | 8-K | 2017-01-03 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On January 3, 2017, Clovis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of 5,000,000 shares of common stock, par value $0.001 per share, of the Company. 8.01 On January 3, 2017, the Company issued a press release announcing the commencement of the offering. | d304815d8k.htm |